154 related articles for article (PubMed ID: 12960734)
1. Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities.
Wang B; Perchellet EM; Wang Y; Tamura M; Hua DH; Perchellet JP
Anticancer Drugs; 2003 Aug; 14(7):503-14. PubMed ID: 12960734
[TBL] [Abstract][Full Text] [Related]
2. Antitumor triptycene bisquinones induce a caspase-independent release of mitochondrial cytochrome c and a caspase-2-mediated activation of initiator caspase-8 and -9 in HL-60 cells by a mechanism which does not involve Fas signaling.
Perchellet EM; Wang Y; Weber RL; Lou K; Hua DH; Perchellet JP
Anticancer Drugs; 2004 Nov; 15(10):929-46. PubMed ID: 15514562
[TBL] [Abstract][Full Text] [Related]
3. Among substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetraones, the lead antitumor triptycene bisquinone TT24 blocks nucleoside transport, induces apoptotic DNA fragmentation and decreases the viability of L1210 leukemic cells in the nanomolar range of daunorubicin in vitro.
Perchellet EM; Sperfslage BJ; Wang Y; Huang X; Tamura M; Hua DH; Perchellet JP
Anticancer Drugs; 2002 Jul; 13(6):567-81. PubMed ID: 12172502
[TBL] [Abstract][Full Text] [Related]
4. Induction of poly(ADP-ribose) polymerase-1 cleavage by antitumor triptycene bisquinones in wild-type and daunorubicin-resistant HL-60 cell lines.
Wang Y; Perchellet EM; Tamura M; Hua DH; Perchellet JP
Cancer Lett; 2002 Dec; 188(1-2):73-83. PubMed ID: 12406551
[TBL] [Abstract][Full Text] [Related]
5. Triptycenes: a novel synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, induce DNA cleavage and decrease the viability of leukemic cells in the nanomolar range in vitro.
Perchellet EM; Magill MJ; Huang X; Brantis CE; Hua DH; Perchellet JP
Anticancer Drugs; 1999 Sep; 10(8):749-66. PubMed ID: 10573208
[TBL] [Abstract][Full Text] [Related]
6. Syntheses, molecular targets and antitumor activities of novel triptycene bisquinones and 1,4-anthracenedione analogs.
Hua DH; Lou K; Battina SK; Zhao H; Perchellet EM; Wang Y; Perchellet JP
Anticancer Agents Med Chem; 2006 Jul; 6(4):303-18. PubMed ID: 16842233
[TBL] [Abstract][Full Text] [Related]
7. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
Wang B; Wu M; Perchellet EM; McIlvain CJ; Sperfslage BJ; Huang X; Tamura M; Stephany HA; Hua DH; Perchellet JP
Int J Oncol; 2001 Dec; 19(6):1169-78. PubMed ID: 11713586
[TBL] [Abstract][Full Text] [Related]
8. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
9. Antitumor triptycene analogs induce a rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria.
Wang Y; Perchellet EM; Ward MM; Lou K; Zhao H; Battina SK; Wiredu B; Hua DH; Perchellet JP
Int J Oncol; 2006 Jan; 28(1):161-72. PubMed ID: 16327993
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM
Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506
[TBL] [Abstract][Full Text] [Related]
11. Antitumor triptycene analogs directly interact with isolated mitochondria to rapidly trigger markers of permeability transition.
Perchellet EM; Wang Y; Lou K; Zhao H; Battina SK; Hua DH; Perchellet JP
Anticancer Res; 2007; 27(5A):3259-71. PubMed ID: 17970069
[TBL] [Abstract][Full Text] [Related]
12. Synthetic 1,4-anthracenedione analogs induce cytochrome c release, caspase-9, -3, and -8 activities, poly(ADP-ribose) polymerase-1 cleavage and internucleosomal DNA fragmentation in HL-60 cells by a mechanism which involves caspase-2 activation but not Fas signaling.
Perchellet EM; Wang Y; Weber RL; Sperfslage BJ; Lou K; Crossland J; Hua DH; Perchellet JP
Biochem Pharmacol; 2004 Feb; 67(3):523-37. PubMed ID: 15037204
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
14. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes.
Meng LH; Zhang JS; Ding J
Biochem Pharmacol; 2001 Sep; 62(6):733-41. PubMed ID: 11551518
[TBL] [Abstract][Full Text] [Related]
15. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives.
Riou JF; Helissey P; Grondard L; Giorgi-Renault S
Mol Pharmacol; 1991 Nov; 40(5):699-706. PubMed ID: 1658605
[TBL] [Abstract][Full Text] [Related]
17. Bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs.
Spicer JA; Gamage SA; Rewcastle GW; Finlay GJ; Bridewell DJ; Baguley BC; Denny WA
J Med Chem; 2000 Apr; 43(7):1350-8. PubMed ID: 10753472
[TBL] [Abstract][Full Text] [Related]
18. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
19. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
Adlakha RC; Ashorn CL; Chan D; Zwelling LA
Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251
[TBL] [Abstract][Full Text] [Related]
20. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Kaufmann SH
Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
